Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Dilutive Common Stock Equivalents (Details)

v3.20.2
Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Dilutive Common Stock Equivalents (Details) - shares
 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Dilutive common stock equivalents 3,994,269 8,093,044
Convertible Notes Payable [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Dilutive common stock equivalents 3,951,225 [1] 8,050,000 [2]
Stock Options [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Dilutive common stock equivalents 39,044 39,044
Stock Warrants [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Dilutive common stock equivalents 4,000 4,000
[1] 3,951,225 shares of our common stock issuable upon conversion of $790,245 of Convertible Notes Payable at a conversion rate of $0.20 per share, as of June 30, 2020, not accounting for 9.99% beneficial ownership limitations.
[2] 8,050,000 shares of our common stock issuable upon conversion of $805,000 of Convertible Notes Payable at a conversion rate of $0.10 per share, as of June 30, 2019, not accounting for 4.99% beneficial ownership limitations.